NeuroThera Labs Inc., a clinical-stage biotech company, has closed the final tranche of its non-brokered private placement, raising C$2.7 million by selling 22.5 million units at C$0.12 each. Each unit includes one common share and one warrant exercisable until August 2029. The funds will be used for general working capital and corporate expenses. The offering awaits final approval from the TSX Venture Exchange, and SciSparc Ltd., the majority owner, participated fully in this tranche.
Oracle's stock price has fallen 54% from its highest point, marking a significant decline. Historically, when Oracle experienced a similar drop, it took more than ten years for the stock to recover fully. This long recovery period highlights potentia...
Wallets tied to North Korea's sanctioned Lazarus Group have moved over $30 million in stolen cryptocurrency through Hyperliquid's decentralized trading platform as recently as August 30. These funds were converted across multiple blockchains before r...
Bitwise Asset Management's XRP spot ETF has reached over $500 million in assets under management just nine months after launching on the NYSE in November 2025. This milestone is notable as it occurred despite a significant decline in XRP's price, ind...
Beta Bionics faces a class action lawsuit for allegedly misleading investors about the safety and effectiveness of its iLet Bionic Pancreas insulin pump. The company claimed FDA concerns were minor and unrelated to device safety, but the FDA's warnin...
Tenor OTC, a non-custodial lending platform powered by Morpho Midnight, has added Aerodrome's AERO token as collateral for fixed-rate borrowing on the Base network. This allows AERO holders to secure loans without selling their tokens, maintaining th...
